RNA Interference from Biology to Therapeutics (eBook)
XVI, 340 Seiten
Springer US (Verlag)
978-1-4614-4744-3 (ISBN)
Kenneth Alan Howard is an Associate Professor and Group Leader at the Department of Molecular Biology at the Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark. His team is based in a highly interdisciplinary setting with research and teaching activities focused on advanced drug delivery, nanomedicine, RNA interference, and inflammation. Dr Howard is CEO of an Aarhus University spin-out company that provides delivery solutions for RNA interference-based therapeutics. Kenneth Alan Howard received a PhD in Pharmaceutical Science from the University of Nottingham, UK in 1995, and has held postdoctoral positions at the CRC Institute for Cancer Studies, University of Birmingham, UK and the School of Pharmacy, University of London. Dr Howard is an active member of the Controlled Release Society serving on the Board of Scientific Advisors (chair), Nominations Committee and organizer of a CRS Educational workshop 'RNA Interference Biology and Therapeutics'.
The enormous potential of siRNA as a therapeutic has led to an explosion of interest from the scientific community. There has been intense interest from Big Pharma to capitalise on this new technology but the fact remains that delivery is a key determinant in realizing the full clinical potential of RNA interference. There is an urgent need for better delivery methods to take this technology forward. This book addresses the role of different RNAi molecules in cellular processes as rational for diagnostic and therapeutic approaches. This book will cover RNAi therapeutic design to optimize siRNA potency and reduce off-target effects and current delivery technologies to overcome both intracellular and extracellular barriers. The reader will gain an insight into RNA interference from the cellular mechanisms to screening to siRNA design right through to diagnostic and therapeutic applications.
Kenneth Alan Howard is an Associate Professor and Group Leader at the Department of Molecular Biology at the Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark. His team is based in a highly interdisciplinary setting with research and teaching activities focused on advanced drug delivery, nanomedicine, RNA interference, and inflammation. Dr Howard is CEO of an Aarhus University spin-out company that provides delivery solutions for RNA interference-based therapeutics. Kenneth Alan Howard received a PhD in Pharmaceutical Science from the University of Nottingham, UK in 1995, and has held postdoctoral positions at the CRC Institute for Cancer Studies, University of Birmingham, UK and the School of Pharmacy, University of London. Dr Howard is an active member of the Controlled Release Society serving on the Board of Scientific Advisors (chair), Nominations Committee and organizer of a CRS Educational workshop “RNA Interference Biology and Therapeutics”.
RNA Interference Pathways and Therapeutic Exploitation RNA Interference.- Synthetic Dicer-Substrate siRNAs as Triggers of RNA Interference.- The Role of MicroRNAs in Natural Tissue Development and Application in Regenerative Medicine.- Intracellular Delivery Considerations for RNAi Therapeutics.- Mucosal Delivery of RNAi Therapeutics.- Nanomedicines for Systemic Delivery of RNAi Therapeutics.- Lipidoids: A Combinatorial Approach to siRNA Delivery.- Polymeric Micelles for siRNA Delivery.- RNAi Therapeutic Delivery by Exosomes.- Aptamer-Mediated siRNA Targeting.- RNAi as Anti-Viral Therapy: The HIV-1 Case.- Genome-Wide RNAi Screen for Identification of Human Host Factors Crucial for Influenza Virus Replication.- The Application of microRNAs in Cancer Diagnostics.- Therapeutic Application of miRNAs in Cancer.- Clinical Development of an Inhalable Anti-RSV siRNA Treatment.
| Erscheint lt. Verlag | 19.10.2012 |
|---|---|
| Reihe/Serie | Advances in Delivery Science and Technology | Advances in Delivery Science and Technology |
| Zusatzinfo | XVI, 340 p. |
| Verlagsort | New York |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
| Technik | |
| Schlagworte | Gene Silencing • microRNA • nanomedicine • nanoparticles • RNAi Clinical Trials • RNA interference (RNAi) • RNAi Therapeutics • siRNA delivery • Small interfering RNA (siRNA) |
| ISBN-10 | 1-4614-4744-5 / 1461447445 |
| ISBN-13 | 978-1-4614-4744-3 / 9781461447443 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 5,6 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
